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ABSTRACT 
Analysis of Embryo Scoring and Comparison of Clinic Performance in In Vitro 
Fertilization 
by 
James Whistler 
Clinical Assisted Reproductive Technology (ART) practices seek to make improvements 
in embryo quality and resultant procedural success rates. There is a significant variance in 
live birth rates among clinics nationwide. The goal of this thesis is make comparisons of 
embryo quality among clinics and understand these differences. This analysis focuses on 
the stage between egg retrieval and embryo transfer. Because the currently accepted 
embryo scoring methods are not directly proportional to performance, a new scoring 
methodology is proposed and applied. Data provided by the Society for Assisted 
Reproductive Technology (SART) consisting of 36,836 patient cycles from 40 
anonymous clinics nationwide is considered. After necessary reductions are made, the 
data is anatomized to link each embryo transferred to an implantation probability. A score 
is generated for each morphology grouping based on the average implantation rate of that 
group. This score is used as the basis for clinic comparisons. Top-performing clinics (in 
terms of live birth rates in patients aged <35 years old) are then shown to both produce 
embryos of higher score and achieve better results from embryos of identical 
morphology.  
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CHAPTER 1: INTRODUCTION 
Every year, many people turn to Assistive Reproductive Technology (ART) to seek 
treatment for fertility problems. A method that has become increasingly viable is In-vitro 
Fertilization (IVF). The IVF process is essentially: 
1. The woman is given a drug treatment to hyper-stimulate ovarian release of eggs 
2. These eggs are fertilized in petri dishes and grown for 3 to 5 days into Embryos 
3. Some of these Embryos are transferred to the uterus  
4. If the transfer is successful, the remainder of the pregnancy continues as would a 
conventional pregnancy 
These steps are illustrated in Figure 1 below: 
 
Figure 1: Process Steps 
This procedure is recognized and performed globally. There are currently 440 
registered clinics in the US (―SART National Summary‖, 2015). Each of these clinics 
aims to maximize positive patient outcomes, namely the delivery of healthy babies. At a 
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high level the process is very similar at each clinic; however, there is a huge disparity in 
live birth rates among clinics. The top performing clinics reporting live birth rates for 
patients aged less than 35 in over 70% of cycles, compared to the lowest performing 
clinics reporting less than 30% (―Fertility Success Rates‖, 2013).  
This thesis aims to take a new approach in analyzing the differences between clinics 
by considering ART practice as a manufacturing process wherein inputs of "materials" 
(patients, gametes, reagents, consumables) and labor are employed under specific 
environmental conditions to produce high quality embryos to initiate pregnancy. To 
facilitate such a comparison and provide a framework for future quality monitoring and 
improvement, a new metric of embryo quality is developed. This research was conducted 
through the exploration of a large dataset provided by the Society for Assisted 
Reproductive Technology (SART). 
This thesis employs data mining and statistical analysis techniques to show 
correlations and trends in the data as well as differences between groups. The power and 
significance of the conclusions are made possible by the large quantity of cases that are 
available for examination.  
The IVF process can be modeled as a manufacturing process: typical manufacturing 
processes aim to reduce defects and improve overall quality. In the context of IVF, this 
means maximizing the quality of Embryos produced. The first step in moving toward 
quality improvements lies in understanding variation in the process. Later designed 
experiments can be used to attach this variation to causation. Subsequently, having 
consistently higher success rates adds additional value to the customers: in this case, the 
patients. This allows clinics who can understand the causes for variation and improve 
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upon them a competitive advantage. This competition will drive improvements across all 
clinics. 
The particular stage of interest of this thesis is that between egg retrieval and embryo 
transfer. In this stage, practitioners want to determine the potential of embryos based on 
what they look like under a microscope. From looking at embryos closely, values of 
morphological categories can be measured objectively, such as the symmetry or 
fragmentation of the embryo. The challenge is translating an array of values into one 
score that reflects the potential of that embryo to result in a successful pregnancy. Several 
scoring methods have been shown to correlate with performance; however, none are 
directly derived from results. These are detailed in the literature review. This exploratory 
study aims to utilize a large dataset to develop a new 1-dimensional Embryo Score based 
upon actual performance. 
After a reliable scoring method has been established, the large dataset can be used to 
compare performance among clinics. Of course, confounding patient factors must be 
considered. After significant factors are removed, how the mean embryo score differs by 
clinic is examined. This measures the quality of embryos produced by clinics. 
Additionally, the difference among clinics in performance of embryos with identical 
morphology (and thus the same score) is explored. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
This literature review serves multiple purposes and accordingly, is divided into 
two main sections: IVF process understanding and exploration of existing research. A 
general overview is provided before diving into more detailed considerations. The IVF 
process understanding begins with a high level exploration of how Assisted Reproductive 
Technology has evolved over time and then focuses on that have changed over the years. 
It discusses the evolution of Assisted Reproductive Technology and the differences 
between the early days of IVF and today’s practices. 
Prominent research objectives in industry studies and reports are reviewed. Also, 
critical methodologies and results are presented, making evident some gaps in existing 
literature. The literature review concludes by discussing how this thesis targets some of 
the existing gaps.   
 
2.2 IVF Process  
In 2011, over 150,000 patients underwent IVF treatment in the United States 
(―Assisted Reproductive Technology‖, 2013). It is estimated that over 5 million babies 
have been born worldwide via IVF since Louise Brown, the first test-tube baby, was born 
in 1978 (―ART fact sheet‖, 2014). Infertility refers to a biological inability to conceive 
after regular, unprotected sex, or a female who can’t carry a pregnancy to full term 
(Nordqvist, 2014). Ovulatory disorders are one of the most common causes for infertility 
in women, accounting for 30% of women’s infertility. Ovulation is the monthly release of 
an egg. In some cases, the woman never releases eggs, and in others, the woman does not 
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release eggs during some cycles (Nordqvist, 2014). Ovulatory disorders are caused by 
issues including hormonal problems, damaged or scarred ovaries, premature menopause, 
and follicle problems (―What Causes Female Infertility‖, 2015). Ovulatory problems can 
result in damaged ovaries, follicles, the production of immature eggs, or no eggs. In these 
cases, chances of fertilization become nearly nonexistent (―What Causes Female 
Infertility‖, 2015).  
Another factor affecting about 25% of infertile couples is poorly functioning 
fallopian tubes, or tubal disease. It is caused by infections, abdominal diseases, previous 
surgeries, ectopic pregnancy, and congenital defects. The fallopian tubes can experience a 
range of issues from mild adhesions to complete blockage, in which case eggs can’t, or 
have trouble being released.  
Endometriosis affects about 10% of all infertile couples. For women with 
endometriosis, their monthly chance of getting pregnant is reduced to 36%. (―What 
Causes Female Infertility‖, 2015). 
Other factors include obstruction of the uterus and fallopian tubes, congenital 
abnormalities, cervical mucus problems, and behavioral factors such as diet, exercise, 
smoking, and drugs, and environmental and occupational factors.  
IVF is a multistep process, or cycle, in which eggs are extracted and fertilized 
with sperm in a lab. Once embryos develop, some are implanted in the woman’s uterus 
(typically 1-3) and if further viable embryos remain, they are stored (Christiano, 2015). 
This process can be used to treat some of the aforementioned infertility problems, 
including: blocked or damaged fallopian tubes, women with ovulation disorders, women 
who have had their fallopian tubes removed, women with severe endometriosis, genetic 
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disorders, and unexplained infertility (Romito, 2013). The success of IVF treatment 
varies by age – yielding 41% pregnancy rate for women under age 35, 32% for women 
ages 35 to 37, and 23% for those ages 38 to 40 (Christiano, 2015). If successful, couples 
with serious fertility problems can become parents. However, treatments can be costly – 
averaging about $8,000 per cycle before medication – and can be physically demanding, 
requiring a regiment of fertility drugs before the start of each cycle (Christiano, 2015). 
These drug treatments can have serious implications for the mother and baby.  
 
2.3 Existing Research 
Challenges in the Field Today: Risks of Higher Order Multiple Pregnancies  
Higher success rates in both oocyte and embryo production have led to 
increasingly alarming rates of twinning and Higher Order Multiple (HOM) pregnancies. 
Across the board, initiatives have been made to suggest moving in the direction of Single 
Embryo Transfer, thus reducing the chance of fraternal twinning to zero.   
A consideration for the biological efficiency of IVF is not a new idea in general. 
Doctors and Researchers have expressed concern for the impacts of the drug therapy 
typically undergone by IVF patients. As mentioned in the IVF Process section, patients 
undergo drug therapy to hyperstimulate the ovaries, resulting in greater egg production. 
However, some claims have been made as to the ―unnaturalness‖ of this drug therapy — 
in some cases releasing 30 or more eggs in one cycle as opposed to the average of 1, or 
rarely more than 3 in a natural ovulation period.  
One study was performed to explore the high biological inefficiency of wasted 
oocytes (Patrizio & Sakkas, 2009). The researchers used data provided by SART to 
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analyze efficiency of the process at each stage, most notably investigating the efficiency 
of each oocyte resulting in embryos and subsequently, successful live births. 
Wasting a few eggs cells may be inefficient, does not pose a high biological risk. 
The larger concern here is the increased risk of twinning and particularly, HOM 
pregnancies. The rates of twinning and HOM pregnancies are significantly higher in the 
IVF process compared to traditional conception methodologies. With each additional 
baby delivered, there is heightened morbidity and mortality risk for both the mother and 
baby (Pector, 2005). Not to mention, the additional financial and emotional burden such 
cases may put on families, who are already spending a good deal of money on the 
procedure itself. 
Due to the risks and costs associated with HOM pregnancies, initiatives have been 
made, across the board, to suggest moving in the direction of Single Embryo Transfer in 
order to reduce the chance of fraternal twinning to zero. 
Transfer of a single embryo requires a high level of confidence in the ability of an 
embryo to implant. A study by Jungheim et al. (2010) discussed the benefits of shifting 
towards fewer and even single embryo transfer. They performed a survey to determine 
how well the American Society for Reproductive Medicine (ASRM) embryo transfer 
guidelines were being followed by practitioners nationwide, showing that 55% of 
responders will deviate from the guidelines upon patient request. This shouldn’t be 
surprising, as this procedure is typically not covered by insurance; patients making this 
investment want to have the best chance of success. They cite the extreme case of the 
Octomom, a well known case of a woman who had 6 embryos transferred, all of which 
implanted and two became identical twins. This was a statistical anomaly and seems only 
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to be referenced in this paper to invoke an emotional response from the reader. Further 
research should be done to assess the probability and risks of HOM pregnancies in order 
to adequately define the upper and lower limits for embryo transfer.  
A study examining the efficiency of oocytes becoming embryos by Patrizio and 
Sakkas notes that the vast majority of embryo transfers in the IVF process happen either 
3 or 5 days after fertilization. An interesting finding within this dataset was that the 
percentage of day 3 transfers is higher as patients get older. This increase is from 68% in 
patients under 35 to 86.7% in patients over 42. This leads to a potential confounding 
factor when comparing Embryo quality across day 3 and day 5 transfers. (Patrizio & 
Sakkas, 2007)  
Patrizio’s study examined 572 retrieval cycles and found that 2252 oocytes 
resulted in usable embryos, which accounts for around 31% of total oocytes retrieved. 
From these, a final live birth rate of 6.8% per oocyte was reported. In patients over 40, 
birth rates per oocyte were below 1%. The authors seem to be appalled by this low 
efficiency rate. The ethical decision becomes whether or not wasting a dozen eggs to 
create a healthy baby that would not have been possible otherwise is certainly worth it. 
They do bring up a plausible hypothesis: some of the oocytes retrieved may be 
intrinsically abnormal and ovarian hyperstimulation may interfere with the intracellular 
events happening here. However, very little is known about the molecular dynamics 
taking place. This is an area that needs more exploration from a biological perspective. 
Patrizio recommends minimal or mild ovarian stimulation, and further exploration 
of such practice. Perhaps his most important point is that producing a higher number of 
oocytes doesn’t result in more viable embryos. To make this more powerful and build on 
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his research, a designed experiment comparing low and high ovarian stimulation in an 
otherwise equivalent environment would be useful. The problem with just an exploratory 
study comparing results based on number of eggs produced could be confounded with 
any number of biological factors. 
Patrizio’s goal is to limit excessive oocyte production and embryo transfer. The 
practical challenge is the high degree of inconsistency in quality, making this a challenge 
without reducing live birth rates. He concludes by calling for a more standardized metric 
to measure IVF efficiency in hopes of promoting greater awareness and encouraging 
improvement.  
Studies focusing on day 5 transfers of blastocysts indicate that transferring more 
than 2 embryos does not provide additional value (Stern et al., 2008). In patients where 3 
and 4 embryos were transferred, lower pregnancy rates results. However, it is likely that 
these situations were a result of the morphologically poor embryos that caused the doctor 
to transfer so many (A. Steinleitner, personal communication, 2015) This goes along with 
the aforementioned idea that the presence of one strong embryo is more important than 
mean embryo score.  
 Many researchers have proposed that Single Embryo Transfer (SET) results in 
lower pregnancy rates with an odds ratio of .53 when compared to double embryo 
transfer (Bhattacharaya & Templeton, 2004). It is important to note that the risk of 
multiple pregnancy is decreased by a factor of 10 in randomized controlled trials 
(Bhattacharaya & Templeton, 2004). In order for SET to be more widely considered, 
probability of patient outcomes must be better understood. 
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Factors Affecting IVF Success 
It is important to understand which factors influence the success of an IVF 
procedure. This paper will examine quality in clinics, so it is important to understand 
what variability exists in the inputs (the patients) and how they influence the procedure. It 
is also relevant to understand the ways in which patient related factors can be practically 
tracked. This allows the clinic to separate what factors they can and cannot affect. 
One of the most widely recognized factors is decreased fertility as women age. A 
retrospective study of 878 IVF cycles indicated that fertility may decrease even sooner 
than the previously widely accepted mid 30’s threshold. (Ziebe et al., 1997) This analysis 
studied 3 clinics over a four-year time span from 1993 to 1996. The metrics that 
researchers focused primarily on were the number of oocytes produced and number of 
cleavage state embryos produced in day 2. The researchers found a highly significant 
decrease in oocyte production as age increased. They also note that the stimulation dose 
is typically increased in older patients. This would suggest that the ovarian response is 
diminished even more than indicated by these results. 
Additionally, they show significance in the decrease of the proportion of oocytes 
that are aspirated into cleavage stage embryos. In each of these cases, the significance is 
easy to demonstrate due to a large sample size. This is certainly valid when making 
comparisons of mean performance by age group. However, the linear model is not 
effective in predicting the performance (Number of oocytes produced and 
Cleavaged/Aspirated Ratio based on age). It is not listed in the study, but from the graphs 
included, it is evident that the R-squared value of the model is very low; thus the 
predictive utility is limited. 
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Further, the researchers zoom in on specific groups. For example, they show that 
there is a negative trend in the implantation rate of good quality 4-cell embryos as age 
increases. (Ziebe et al., 1997) This demonstrates that, all other factors considered equal, 
an increase in patient age will have a negative effect on embryo performance. 
Another study was done to examine the effect of max Folicule-Stimulating 
Hormone (FSH) level on ART treatment outcomes. FSH helps control production of eggs 
by the ovaries. Considering a large sample from SART data of 19,682 cycles in 1999, it 
was shown that a significant negative correlation exists between maxFSH and treatment 
outcomes. (Frazier, L. , Grainger, D., Schieve, L., & Toner, J., 1999) In other words, as 
FSH level increases, pregnancy rate and live birth rate decrease. It will be interesting to 
compare these results with those in the 2009-2011 data examined in this paper.  
Additionally the study found a weaker but still significant correlation between 
estradiol-17beta, commonly referred to as E2 level and treatment outcomes. These 
correlations were shown individually in each age grouping. A noted limitation of this 
dataset is that the patients’ max FSH level is tracked in each case, but the day of the cycle 
in which this information was obtained is not available. Therefore, it is unclear whether 
the data comes from a basal measurement on the second or third day of the cycle or from 
a Clomid Challenge Test (CCCT) result that is typically measured on day 10.  
In contrast to Frazier et al.’s research, a 2003 study found that FSH level alone 
was not a significant factor in affecting treatment outcomes. However, FSH level was 
significant when considered jointly with age.  
An excellent point is made in that patients will heavily weigh their chance of 
successful pregnancy when considering whether or not to undergo the IVF process. This 
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information is critical for counseling patients. The more accurately practitioners can 
predict the expected success at each phase in the process, the more informed patients will 
be as a result.  
One of the major factors impacting a patient’s chance at success is their age. 
Ovarian reserve, defined as the quality and quantity of the remaining follicle pool 
(Chuang et al., 2003), is shown to diminish in most women during their mid to late 30s. 
Ovarian responsiveness to stimulating drugs has been shown to be a strong indicator of 
IVF treatment outcomes and is a useful metric to track.  
Chuang’s study (2003) focuses on the patients undergoing treatment at the 
National Taiwan University over a 5-year period spanning 1,045 treatment cycles. All 
cycles examined were the first undergone for each woman. This study split up patients 
into 3 age groupings (<35,35-39,>=40) and 2 basal FSH groupings (<10 mIU/mL and 
>10mlIU/mL) resulting in 6 combinations. 
Based on a logistic regression analysis, they found age to be an independent 
predictor of pregnancy rate, but not basal FSH. When both are in the model together, the 
AUC (area under receiver operating characteristic curve) raises from .617 to .627 — a 
minimal improvement. However, age and basal FSH together make for the most effective 
predictor of number of oocytes collected. (Chuang et al., 2003) This study is 
demonstrative of the benefits of tracking data reliably over a long period of time in 
drawing significant conclusions. Chuang concludes by saying that although FSH is 
related to age, and each is related to ART success, the predictors are not perfectly 
correlated with outcomes, and more research is required. 
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Dr. Stern and her colleagues focus on patients over 38 years old in their aim to 
determine the optimal number of embryos to transfer in these situations examining 
factors such as prior pregnancy, FSH levels, number of oocytes retrieved, and number of 
embryos cryopreserved. They focused on these factors because the uncertainty is greater 
in older patients and the risks associated with HOM pregnancies are greater. Their goal 
was to develop an algorithm indicating the optimal number of embryos to transfer in each 
case. However, the study primarily looks at correlation between variables which are 
procedural inputs. An examination of each variable’s effects on output would be more 
useful. Potential measures of output could be implantation or live birth rate. 
Nonetheless, Stern et al. (2009) did find an interesting correlation between 
number of embryos cryopreserved and delivery rate. From a logistic regression analysis, 
they found a relative risk of pregnancy to be .77 in patients with less than 5 embryos 
compared to those with greater than 15 frozen with significance (P<0.001). This is 
certainly something that should be considered in future studies. Number of embryos 
cryopreserved seems to be a good indicator it is a good indicator of process stability. 
They also noted that some centers are ―day 3 only‖, meaning they either don’t have the 
capability or choose not to grow embryos beyond this. This is interesting information that 
could not be derived from the SART dataset, as clinics are not uniquely identified.  
When they did look at output, this study used pregnancy rate by patient as a 
metric. This doesn’t account for the number of embryos transferred and perhaps 
oversimplifies what would be better measured using implantation rate. Mentioned is the 
need to explore the impact of individual clinics due to different procedures and success 
rates. 
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Another group of factors that can be highly indicative of the IVF treatment 
outcomes are embryo morphological characteristics. Scoring based on these 
characteristics together is a focus of many studies. In particular, the effect of 
fragmentation in day 3 embryo success has been explored extensively. From a sample of 
5,916 embryos, the average fragmentation was 15.4% on day 3, and 8.6% in those 
embryos that replaced. The mean implantation rate (IR) for this data set was 29.9% 
(Alikani et al., 1999). There is a high degree of significance in difference of embryo IR 
and pregnancy rate by fragmentation (p<0.05). However, Alikani points out that this is 
largely due to the extremely poor performance of embryos in the worst grouping, with 
greater than 35% fragmentation. The researchers found no correlation between 
fragmentation pattern and maternal age. They also found minimal impact of 
fragmentation removal, when it was possible. It is proposed that further research could be 
conducted on the impact of different patterns of the fragmentation rather than merely a 1-
dimensional percentage. 
 
How To Measure IVF Clinic Success 
Dr. Gibbons and his colleagues (2007) bring a fantastic perspective to the major 
dilemma facing ART practitioners. They recognize the major goals that exist: 
1. Improve Live Birth Rates from IVF process 
2. Reduce the occurrence of twinning and HOM pregnancies  
Goal 1 can be easily achieved by transferring more embryos and goal 2 can be achieved 
by transferring fewer. The challenge is to make simultaneous progress on both fronts. 
Thus, it is necessary to either improve the consistency of the embryos produced or 
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develop a better way to predict the success of embryos. The first option requires 
biological or procedural advances while the second, merely a better understanding of the 
data that exists and perhaps additional information-tracking in the future. Better 
understanding and predicting the success clear target area for improvement. 
Dr. Gibbons examined data from the ART nationally reported data and makes an 
astute observation: the lower performing clinics compensate for lower implantation rates 
by transferring more embryos. This results in higher twinning and triplet rates. He raises 
the question: ―Should we be reporting implantation rates instead of live birth rates to 
more accurately reflect program quality?‖ (Gibbons et al., 2007). The counter 
consideration here is: does this merely reflect the patient quality of that clinic?  
Another thing that Dr. Gibbons considers is the idea that patients are extremely 
sensitive to slight changes to implantation rate and, for example, will drive to the next 
city to use a clinic that has a 43% success rate vs. a 38%. This puts tremendous 
competitive pressure on clinics to produce a high birth rate and is likely what motivates 
the higher embryo transfer numbers in the poor clinics. He suggests instead showing 
number of standard deviations away from the national mean in order to downplay small 
differences. Dr. Gibbons is strongly against government regulation as the field is quickly 
changing and he feels that it does not provide adequate flexibility for individual situations 
and could therefore inflict unnecessary financial hardships on infertile couples.  
In light of the data that Dr. Gibbons studied, it is clear that ART practitioners are 
motivated by self interest to improve their relative success. Accordingly, the measure of 
success that is most widely used should be consistent with making advancements toward 
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the two goals outlined by Gibbons above with the appropriate weighting. In 2004, an 
important debate was conducted to achieve this, headed by Min et al. (2004).  
ART is becoming better established and is no longer an experimental procedure as 
it was in the early 90s. In the early stages, the goal was to try to create a miracle in the 
form of a successful pregnancy for a previously infertile couple. Since then, success rates 
have increased markedly as techniques have been refined and improved. In 2004, a very 
important debate occurred in the community to figure out what the most relevant standard 
of success in assisted reproduction.  
Min et al. (2004) argued that the singleton live birth rate should be used as the 
most relevant metric of ART success. In particular, they point to the statistic BESST 
(Birth Emphasizing a Successful Singleton at Term). The authors point out that there is a 
significantly higher risk of complications. Also, the cost of delivering HOM pregnancies 
is notably higher, at $170,282 for triplets, and $281,698 for quadruplets compared to 
$58,865 for twins (ESHRE, 2000). It is important to emphasize that they are considering 
a case of multiple live births to be the same value as an unsuccessful pregnancy or no 
pregnancy at all based on this metric. 
 Countering Min and his colleagues, Davies et al. (2004) contested that looking at 
the BESST measure alone biases the data because it is strongly influenced by extremes of 
age and embryos transferred, namely, patients over 35 or those who electively selected to 
transfer fewer embryos. It is not appropriate to measure the quality of the ART facility 
based on these factors. Additionally, the denominator comes from the number of cycles 
initiated. Since many cycles are unsuccessful in their early phases as they are unable to 
achieve a reasonable fertilization rate due to patient related factors.  
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Davies (2004) emphasizes that the goal is to measure and minimize the degree of 
burden or unwanted consequences and points out that it’s difficult to measure this with 
only one parameter. For example, if implantation rates increase for a particular clinic, the 
overall pregnancy rate will increase, but so will the occurrence of multiple pregnancies 
— thus the BESST rate will change unpredictably. 
Contributing to the discussion, Heijen et al. (2004) agreed that singleton live 
births are the goal, but the patient discomfort, risk of complications and costs should be 
considered. The measure of success should reward a clinic that produces a similar birth 
rate with milder ovarian stimulation and single embyro transfer compared to a clinic that 
transfers 3 or more embryos in young patients. A key point is that there is a dropout rate 
of approximately 25% after an unsuccessful process. The authors affirm that this is not 
only due to the cost factor or a poor prognosis, but also that the treatment process itself 
can be emotionally and physically stressful. In order to encourage clinicians to reduce the 
stressfulness of the process, the authors suggest that he denominator of success rate 
measure be number of treatments started rather than number of cycles.  
Heijen (2004) mentions the idea of giving a higher value to the outcome of twins 
over an unsuccessful cycle rather than only crediting a singleton birth. For example, a 
singleton could be scored 1, and twins 0.5.  
It is important to consider the implications of adopting a universal metric of IVF 
success. Clinics are businesses that compete with one another and will do what they can 
to improve this metric and increase their market share. Patients are motivated by clinics 
that they feel will give them the best shot at being successful in having a baby, so it’s 
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likely that they will likely pay more or travel a considerable distance. As a result, 
clinicians will certainly aim to improve their score. 
Changing the metric from singleton births per cycle to singleton births per stared 
treatment helps encourage practitioners to shift towards elective single embryo transfer 
and milder ovarian stimulation. This advances the goals of decreasing negative 
consequences of IVF procedures such as HOM pregnancies or excessive stress on the 
mother. 
 
Attempts at Developing an Effective Embryo Scoring System 
It is useful to understand the relative value and the absolute value of an embryo 
based on its morphological characteristics. That being said, there has been significant 
research done in attempt to develop a method of scoring embryos based on easily-
measurable data. However, to this day, there is no single widely-adopted method. 
Surprisingly, the study that has been most predominant in the community — and still 
relevant today — is from 1986. Given that IVF processes have evolved so much means 
that there are holes in what is established and new research is needed to fill these gaps. 
Reviewing some of the literature documenting attempts to develop a scoring method will 
show where the research stands. 
A study done by Cummins et al. (1986) was one of the first attempts at 
establishing a reliable method with which to score embryos. This paper is extremely 
important in this literature review as it was the first and most widespread attempt at 
generating an embryo score and was widely accepted by many in the ART community. 
Their goal was to establish a general method for determining the quality of embryos 
19 
 
based on visually apparent criteria, thus making predictions as to the performance of said 
embryos. They use two main criteria in scoring embryos: Embryo Development Rating 
(EDR), and a 1-4 scale of Embryo Quality (EQ) with 4 being the highest. The EDR is 
based on a regression model for the mean growth rate, and the visual quality (EQ) metric 
is derived from fragmentation, symmetry, and cytoplasm quality. 
Cummins and his colleagues established groupings for EDR and EQ combinations 
and calculated ―success rates‖ for each grouping. Success rate is not identical to 
implantation rate and is instead the probability that an embryo with this EQ/EDR 
combination will be associated with a successful pregnancy. This causes an inherent bias 
in their results and must have only been used due to an inability to track which embryo 
was successful in the situation of multiple embryo transfer. Considering this, the 
researchers looked at the 357 cases they had available with single embryo transfer (of 
which 33 were successful) and were able to show significance in some groups however 
the power of these results was limited due to the small sample size.  
Still, on the basis of the success rate metric, comparisons can be made between 
EQ/EDR combination groups. Significant differences were found between many of the 
groupings. The highest rate of success in the category with EDR slightly above average 
and EQ is maximized (4). Also, the fastest growing embryos (EDR > 130) did not show 
an increased pregnancy rate over the dataset average. 
A study by Ziebe et al. (1997) examines the effects of morphological components 
as defined by Cummins in 1986 (quality score and cleavage stage) on implantation rate. 
They focus on 3 clinics over a 3 year timeframe resulting in 1001 transfers of 1918 
embryos. These clinics transferred embryos on day 2 and found 2 notable conclusions: 
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(1) Implantation rates were significantly higher for 4 cell embryos (23%) than 3 cell (7%) 
or 2 cell (12%); and (2) Significance in the difference between the IR of the best and 
worst morphology groups. It would be interesting to see the how the differences between 
each morphology grouping are presented when a larger sample size is examined. 
Another attempt at predicting the results of IVF procedures focused on both 
zygote scoring and embryo morphology as determining factors for IVF success (De 
Placido, 2002). This research found minimal correlation between zygote scoring and 
resulting embryo morphology (r =0.1). With 15% of the poorest quality zygotes 
producing viable embryos, it is not strong enough to suggest that a low quality zygote can 
be thrown out. Additionally, minimal impact on pregnancy or implantation rates was 
shown in comparing good and poor quality zygotes. The key takeaway here is that 
embryo morphology is much more predictive than zygote score. Their results, albeit from 
a small sample size (183 patients) confirm Cummins’s 1986 analysis of a correlation 
between EDR and embryo success, and suggest that this is more powerful than looking at 
zygote or embryo morphology scores alone. They also mentioned that the presence of one 
good quality embryo was more important than the mean embryo score. 
Another proposal was generated to score embryos on a 4 point scoring method for 
day 2 embryos. This study focused on 957 single embryo transfers (Giorgetti et al., 
1995). Looking only at single embryo transfer cases is an interesting limitation. The 
benefit is that it eliminates any confounding effects that could collectively affect embryos 
in a multiple embryo transfer. Perhaps more importantly, it removes the inherent 
uncertainty that results from cases such as: two non-identical embryos are transferred and 
one is successful. It would be nearly impossible and certainly very costly to track which 
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of the embryos implants. The drawback is that this subset of patients consists of not only 
elective single embryo transfers but also patients in which only one viable embryo was 
available. This latter effect could cause some confounding effect of less viable patients 
compared to the overall pool. The researchers found several significant factors that 
affected pregnancy rate. One was rate of development: 4 cell embryos implanted twice as 
well as slower or faster growing embryos. Also, they found that in 99 cases of uncleaved 
(1 cell) embryos, 3 pregnancies and 0 live births. Based on this a 4 point scale was 
derived with one point given for each of the following: 
1. Cleaved embryo presence 
2. Minimal or no fragmentation 
3. No irregular blastomeres  
4. 4-cell stage 
A significant correlation was shown between the embryo scores and both pregnancy rate 
and take home baby rate. Interestingly, the researchers did not show any difference in 
embryo score between younger patients and older patients (age > 38).  
Each of the components of this score is individually significant in terms of their 
effect on pregnancy rate. However, each effect is not equivalent in magnitude. The 
authors are not clear as to the criteria they used to decide on the weighting. 
A major prerequisite in achieving the goal of reducing multiple pregnancies and 
shifting towards single embryo transfer is being able to identify embryos with a high 
implantation potential. The best way to know more about the potential of any embryo is 
to grow it for longer i.e. wait until day 5 to transfer instead of day 3. The issue with this is 
that culturing practices are not perfect; there are fewer embryos suitable to transfer, 
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leading many clinics to transfer earlier. (Royen et al., 1999) This raises the question, were 
the embryos that became unviable between day 3 and day 5 never going to have the 
potential to result in a healthy baby, or can this sometimes be a result of an exogenous 
factor from the laboratory?  
Royen et al. (1999) believed the latter is true. This would indicate that a clinic can 
improve by eliminating these exogenous factors and improve their success by doing more 
day 5 transfers. Certainly it is not that simple, as it is very difficult to even identify what 
these factors may be, not to mention remediate them. This will require many future 
designed experiments and likely significant costs if the factors are precise control of 
temperature or air quality, for example. 
Royen et al. (1999) took another approach; he said that if he can better identify 
which embryos are most viable earlier on in the process, the same embryo selection can 
be achieved with an earlier transfer. Thus, lower exposure to problems that could occur 
during the culturing. 
To explore this, he conducted a study to try to identify the best criteria to evaluate 
embryo potential. He scored embryos based on (i) fragmentation (ii) number of 
blastomeres and (iii) number of multinucleated blastomeres and recorded the three 
criteria on day 2 and day 3 of each cycle. This sounds very promising to have such 
detailed information tracked. Unfortunately, Royen’s sample size is quite small and his 
results have limited significance.  
His study examines 400 cases over 2 years at a clinic in Belgium using relatively 
homogeneous drug treatment and transfer procedure. In order to characterize high quality 
embryos, they look at the 23 cases where 2 embryos are transferred and a dizygotic twin 
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pregnancy occurs. In these 46 embryos, none of them were fragmented and the majority 
had 8 blastomeres on day 3. 
Royen et al. (1999) claimed that they ―preferred not to set an upper limit because 
the faster an embryo cleaves, the more likely it is to implant successfully.‖ This is not 
consistent with other studies performed on larger sample sizes that indicate embryos that 
grow too fast have reduced performance (Cummins et al., 1986). It is also mentioned that 
no article to date has described the embryos with maximal implantation rate. Further, the 
relative potential of embryos of differing morphology combinations has not been 
explored extensively. 
 Light has been shed on the lack of a universal, reliable Day 3 scoring system since 
the early days of IVF. Desai (2000) considers several methods of scoring embryos in 
attempt to better predict their potential in resulting in a healthy baby. The 3 proposals are 
listed below: 
1. Number of cells 
2. Number of cells - 2 points if heavily fragmented 
3. Number of cells - 2 points if heavily fragmented + 0.4 points for each positive 
feature: (Blastomere expansion, All equal size, Absence vacuoles, Pitting, Compaction)  
Desai and her associates considered 316 embryos from 93 patients to test the validity of 
the scoring methods. In each of the 3 methods, the score obtained from the pregnant 
group was significantly higher than the not pregnant group. But is this significant 
difference enough to provide useful predictive information or relative value of these 
embryos? Desai also looks at the actual average implementation rate of each category.  
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The authors of this study point out that in many cases, they have several day 3 
embryos with similar cell counts and levels of fragmentation and need additional ways to 
determine the best embryo to transfer. Hence, they derived the 5 morphological 
parameters added to their score. Based on their data, they are that these morphological 
parameters have greatly improved their ability to decide on the optimal embryos to 
transfer. The challenge will be to standardize the tracking of these parameters in a large 
dataset across multiple clinics to see if the results are confirmed. 
Interestingly, the 5 morphological predictors were not significant on their own in 
predicting outcome, however when combined in the score they were. This could be due to 
the fact that the number of cells was by far the largest component of the score, and 
number of cells is very significant.  
The drastic improvement in the 1990’s of drug treatments in ART technologies 
and the resultant ability to produce more eggs and embryos has been well documented 
(Hu et al., 1998). As embryos are more plentiful, it becomes increasingly important to 
understand how to score embryos absolute and relative potential. More effective scoring 
will lead to both higher instances of singleton pregnancy and lower rates of unwanted 
multiple pregnancies.  
A scoring system is proposed as a 1-5 grading creating groupings based on 
combinations of number of sells, equivalence of blastomere size and 
fragmentation. This grade is then subtracted from 5 to obtain an embryo scoring. 
Table 1 shows the breakdown: 
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Table 1: Embryo Grading and Score System 
 
Adapted from Hu et al. (1998) with permission 
Then, Hu added the mean embryo scores for each case to create a ―mean 
cumulative embryo score‖ for all of the embryos transferred in each cycle. Perhaps 
―cumulative mean embryo score‖ would be a more intuitive naming scheme. The issue 
with using a cumulative scoring for all embryos transferred is it provides a much higher 
score for cases where more embryos were transferred. Further, adding scores together 
makes the assumption that the probability of implantation of one embryo is independent 
of the probability of another (possibly identical) embryo implanting in the same uterus.   
Regardless, 754 consecutive patient cycles were scored. The patients were split up 
into 3 age groupings (<36, 36-39, >39). Also the MCES was split up into (<10, 10-19, 
>19). In every case, there was an upward trend of implantation, pregnancy and multiple 
pregnancy rate. The MCES is an attempt at assessing quality and number of embryos 
transferred in one metric. Hu (1998) shows that higher-order multiple conceptions are 
more prevalent in higher quality embryos in younger patients as well as obviously in 
cases where more embryos are transferred. He goes on to suggest a recommended 
number of embryos to transfer in each case. In patients under 36, he suggests transferring 
up to 4 poor quality, 2 fair quality, or 2 good quality embryos. 
A key discussion centers around the evaluation criteria for determining the best 
embryo(s) to transfer. Suggestion has been made that in many cases the selection is based 
more on clinical tradition than scientific evidence (Matchinger 2013). Matchinger 
mentions a key challenge of making accurate assessments of embryo evaluation 
Grade Score Morphology
1 4 ≥5 cells; blastomeres of equal size; 0 cytoplasmic fragments
2 3 ≥5 cells; blastomeres of equal size; ,30% cytoplasmic fragments 
3 2 ≥5 cells; blastomeres of distinctly unequal size; 0 cytoplasmic fragments 
4 1 ≥5 cells; blastomeres of equal or unequal size; 30%–50% cytoplasmic fragments if equal or 1%–50% fragments if unequal
5 0 <5 cells of any size, or any pre-embryo with .50% cytoplasmic fragments
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methodologies due to the challenge of assessing a large enough homogeneous sample. 
Either the sample will be limited in size when coming from a particular clinic, or it will 
be biased by differing patient selection or evaluation criteria by different clinics. Every 
embryo is unique and the line that one doctor draws between a moderately and severely 
asymmetric embryo may not be identical to another.  
Blastocysts (typically found in day 5 transfers) are generally scored by the method 
proposed by Gardner et al. (2000). Gardner’s system considers the stage, the inner cell 
mass and trophectoderm. His score and has been shown to be more effective in predicting 
IR even than more recently developed methods. From this, SART has developed a 
standardized embryo scoring method; the complete array of levels for each descriptor is 
shown in Table 2: 
Table 2: Gardner's System for Scoring Blastocysts  
 
Adapted from Matchinger et al. (2013) with permission 
Even with a standardized scoring system, there is a degree of intra-observer and 
inter-observer variability in scoring. Some studies have focused on measuring this such 
as (Paternot et al., 2011a) which had 5 embryologists look at the same embryos and 
Blastocyst Stage Grade  Characteristics
Early blastocyst 1 The blastocoele is less than half the volume of the embryo 
Blastocyst 2 The blastocoele is greater than or equal to half of the volume of the embryo
Full Blastocyst 3 The blastocoele completely fills the embryo 
Expanded Blast. 4 The blastocoele volume is larger than that of the early embryo and the zona 
pellucida is thinning Hatching blastocyst 
Hatching Blast 5 The trophectoderm has started to herniate through zona pellucida 
Hatched Blast 6 The blastocyst has completely escaped from the zona pellucida 
Inner cell mass A Tightly packed, many cells
B Lososely grouped, several cells
C Very few cells
Trophectoderm A Many cells forming a tightly knit epithellum
B Few cells
C Very few cells forming a loose epithellum
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compared their assessment. Variation was deemed relatively low, but the fact that some 
exists is demonstrative of the challenge in developing standardized criteria for evaluating 
day 3 embryos. 
The primary effort of formulated embryo scoring considering multiple criteria 
together was by Cummins’ 1986 study, however these results are reflective of a very 
early stage in the process. Matchinger mentions that more work needs to be done to 
revise these results and consider them in the context of a larger dataset and modern 
practice techniques. 
Dr. Gibbons (2007) discussed why it is necessary to make improvements in the 
predictability of IVF cycles. One area where this is vital is surrounding the key decision 
of the IVF process: which and how many embryos to transfer. Thus, it is necessary to 
understand the factors that can affect the performance of an embryo. As described in 
detail in an earlier section, the morphological criteria examined for each type of transfer 
are primarily number of cells, symmetry and fragmentation for day 3 embryos. For day 5 
embryos, stage (hatching, expanded, or early blastocyst), inner cell something and 
trophectoderm morphology.  
The largest study on exploring the impact of these morphological predictors is Dr. 
Racowsky’s 2003 study, which looks at a SART dataset of 5,112 patients from 1998 to 
2001. This study brings up a very important point: the relative value of day 3 
morphological combinations and embryo viability remain ill defined. The last attempt at 
establishing an embryo score was by J.M. Cummins (1986).  
Quite logically, Racowsky and her colleagues focus on the output of implantation 
rate measured by week 8 fetal heart rates rather than pregnancy rates. They argue that 
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problems that occur past week 8 are more likely due to biological complications not 
related to embryo quality. Also, in addressing the same issue that Cummins faced, of not 
knowing which embryo implants in the case of multiple embryo transfer, they used a 
fairly innovative strategy: consider all of the cases in which the embryo’s fate is known: 
1. Either all or none of the embryos implanted 
2. All of the embryos transferred are morphologically equivalent 
The researchers looked at a group of 1,823 embryos transferred on day 3 all from patients 
younger than 37 years old. They considered the effects of fragmentation asymmetry and 
number of cells univariately and found significance in each case. They then proposed 
viability percentages shown in Table 3 – Table 5 below: 
Table 3: Interaction of Conventional Day 3 Morphology Markers as Predictors of 
Viability 
 
 
Table 4: Cleavage Stage on Day 3 and Viability of Expanding/Expanded  Blastocysts on 
Day 5 
 
Different superscripts indicate a significant difference, a versus b, p < .04. 
 
 
 
Cell no. %Fragmentation Asymmetry % Viable
8 <10 None 35
8 10-25 None ~25
8 <10 Some or severe ~25
>8 <25 None or some ~25
8 10-25 Some or severe 10-15
7 <25 None or some 10-15
Others <5
Cell no. on Day 3 No. embryos Transferred No. embryos Viable (%)
<7 14 6 (42.9)a
7 28 16 (57.1)b
8 126 69 (54.8)b
>8 26 9 (34.6)
a
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Table 5: Fragmentation on Day 3 and Viability of Blastocysts on Day 5 
 
No significance difference was found between the groups. 
 
Tables 3 – 5 adapted from Racowsky et al. (2003) with permission. 
They also studied some day 5 embryos but the sample size was quite small (258 
embryos). This study was performed based on data from one clinic and provides an 
important foundation for the methodology of assessing embryo quality based on 
morphological predictors. This study is fairly similar to ours but it uses a much smaller 
dataset. 
 It is evident from the research that has been done that there is interest in better 
understanding the impacts that embryo morphology has on treatment outcomes. Several 
researchers have sought to develop a universally applicable embryo score. The most 
robust methodology seems to be that of Racowsky et al. (2003) which derives a score 
directly from performance.  
Advancements in data tracking facilitated by SART, among others, have allowed 
for larger sets of data to be available for analysis. This thesis will employ a methodology 
similar to Racowsky et al. to data from 40 clinics in an attempt to understand the value of 
embryos of various morphologies. These values will be comparable in one-dimension and 
allow clinics to track their performance accurately.  
 
 
  
Percent Fragmentation on Day 3 No. embryos Transferred on Day 5 No. embryos Viable (%)
0 37 22 (59.5)
1-9 89 51 (57.3)
10-25 23 10 (43.5)
>25 5 2 (40.0)
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CHAPTER 3: METHODOLOGY 
3.1 Exploration of SART-CORS Dataset 
      This retrospective study is based on a large dataset provided by the Society for 
Assisted Reproductive Technology (SART). The dataset obtained from SART contains 
information about 36836 cycles from 2009-2011. What distinguishes this dataset from 
many others that have been considered in previous studies is its size and its breadth.  
      Rather than coming from one or a couple of clinics, this data comes from 40 clinics 
across the United States. Since there is known to be considerable variability between the 
performance among clinics, it is important to ensure that the dataset sufficiently 
encompasses the population characteristics. To do this, the clinics were ranked by their 
live birth rate in patients under 35. Then 4 clinics were randomly selected from each 
decile of the ranking (i.e. 4 clinics between the 1st and 9th%ile, 4 from between the 10th 
and 19th %ile, and so on). The patient cases from these clinics represent the dataset upon 
which the conclusions of this study are based. 
      Due to doctor patient anonymity requirements, the individual clinics cannot be 
identified. Each cycle is given a unique identifier, but is not attributed to a particular 
clinic. The uniqueness of the dataset provides both opportunities and challenges. It is 
differentiated by the sheer quantity of data, which adds considerable power to the 
conclusions drawn. Also, it allows comparisons to be made between the best performing 
clinics and the poorer performing clinics.  
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 The information included can be broken down into 3 main categories, shown in Table 6: 
 Table 6: Dataset Contents 
 
All of this data can be overwhelming at first, with dozens of columns for each of 
the 36,836 entries. It was necessary to cater the data to the specific research objective of 
the study: comparison of clinics. The data is translated into usable information, which 
will improve understanding and ultimately drive actions by IVF practitioners in order to 
move in the direction of their goals: improving success rates and predictability of embryo 
transfers. 
As is typically the case with such a large dataset, not every entry will be usable. 
Particularly, this is true when dealing with compiled data that is entered by many 
different people; each clinic’s data reporting is not going to be perfect. Throughout the 
analysis, reductions will need to be made to maintain accuracy. It will be documented in 
each case when such reductions are made. The major adjustment that is initially made is 
removing the 6685 listed cases in which all embryos are cryopreserved (frozen) and 0 
fresh embryos are transferred and. Since this study focuses on fresh embryo transfers, 
these cases are not relevant. 
The first stage is using drug treatment to cause ovarian hyper stimulation and 
cause the woman to produce a high number of eggs during a particular menstrual cycle. 
Although there is significant amount of variability from one patient to the next, there 
doesn't seem to be a huge impact of clinic related factors on this stage. The overall 
average number of eggs produced in young patients (Age <36) is 14. As detailed in the 
Category Information Included
Patient Information Age, Height, Weight, Diagnosis, FSH level
Embryo Information Morphology characteristics for Each Transferred Embryo
Cycle Inputs and Outcomes Embryos Frozen, Transferred, Implantations, Pregnancy, Live births 
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chart on the next page, the avg. number of eggs retrieved from young patients (<36) does 
not significantly differ among clinics. Although there is a very slight upward trend, in 
each case, the range stays between 12 and 16 eggs. This is illustrated by Figure 2. 
 
Figure 2: Average Oocytes Retreived in Patients <36 
The stage of the process is where things really get interesting from a clinic 
perspective is growth of an egg into and embryos over the course of the first 3-5 days 
after fertilization. The reason this is important is the clinic is able to have a significant 
influence on the performance of this stage. These three to five days are the key 
differentiator between IVF from a traditional pregnancy. This short amount of time is 
extremely critical and can have a major impact on the success or failure of the treatment. 
Rather than inside of a woman’s body which has evolved over millions of years to 
naturally regulate temperature and other factors that may influence the embryo’s 
development, the young zygote is growing in a petri dish in a laboratory where it can be 
potentially exposed to many external factors such as impediments in the air or changes in 
temperature or humidity. These are merely speculative examples of factors that could 
potentially influence embryo success.  
Since it is the portion of the process most controlled by the clinics, the early stage 
of embryo development pre-transfer is the most analogous part of the process to a 
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traditional manufacturing process and the focus of this study. The clinics aim to control 
the output of this stage: viable embryos. The relevant measure of success from this stage 
is the Per Embryo Implantation Rate (PEIR). In the simplest terms possible, PEIR 
measures the portion of embryos transferred that result in a successful implantation. 
      
                       
                        
 
 Since the objective of IVF clinics is to grow viable embryos, the most objective 
way to measure the viability of these embryos is by examining their real performance. 
Although it is quite commonly said in colloquially dialogue ―you can’t be half pregnant‖, 
growing humans is not as black and white as manufacturing metal castings, there are 
many treatment outcomes that can occur. As a result, the calculation must take into 
account many nuanced cases that are present and well documented in the SART dataset. 
 The PEIR calculation was made in the SART dataset using several columns of 
information available. The denominator is very straightforward; it is simply the quantity 
of fresh embryos transferred to the uterus on either day 3 or day 5.The numerator is much 
more complex and is calculated based on the following criteria shown in Table 7: 
Table 7: Implantation Calculation 
IF Implantations = Rationale 
TreatmentOutcome_Not 
Pregnant (col AS) = Y 
0 Pregnancy test was negative hence, no 
embryos implanted 
TreatmentOutcome_Biochemi
cal (col AT) = Y 
1 Pregnancy test was positive, therefore 
AT LEAST one embryo implanted; 
however since nothing is visible on the 
ultrasound at 6 to 8 weeks, cannot know 
if more than one implanted, so by 
convention, a value of "1" is assigned 
TreatmentOutcome_Ectopic 
(col AV) = Y 
1 This is a tubal pregnancy; while it is 
possible to have more than one implant 
in the tubes it is very uncommon, so by 
convention a value of "1" is assigned 
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TreatmentOutcome_Heterotop
ic (col AW) = Y 
UltrasoundFetalH
earts +1    
Very uncommon situation wherein there 
is both an implantation in the fallopian 
tube + implantation in the uterus; it 
would be extremely uncommon to have 
more than one in the tube, so we assign 
a value as above. 
 
TreatmentOutcome_Clinical 
Intrauterine Gestation = Y 
And 
UltrasoundFetalHearts = 0 
1 Early miscarriage; there is at least one 
implanted embryo 
 
TreatmentOutcome_Clinical 
Intrauterine Gestation = Y 
And 
UltrasoundFetalHearts > 0 
UltrasoundFetalH
earts 
Pregnancy 
The formula used to calculate implantations in excel is shown in Appendix C.1.  
On the other side of the spectrum is the final stage of the process in which the 
implanted embryo grows into a baby. This portion of the development is again very 
dependent on patient: it is happening quite literally inside of the patient. To verify this 
assumption, consider the translation between implantation rate, calculated as described 
above, and live birth per embryo transferred. As seen in Figure 3, the ratio of 
implantation rate to live birth remains relatively constant among clinics. 
 
Figure 3: Implantation Rate to Live Births per Embryo Transferred Comparison 
35 
 
There has been significant debate as to what the most relevant output metric is to 
measure IVF clinic success (Min et al., 2004; Davies et al., 2004) and there debate is 
certainly merit to the arguments for considering singleton live birth rate as such. 
Singleton live birth is the goal of the IVF process so the portion of cycles that result in 
this is definitely an important metric when talking about clinic performance. However, 
PEIR is the direct outcome of the particular stage of the process within the control of 
clinics. Therefore, PEIR is the most relevant outcome and will be the metric of interest 
throughout this study.  
Patient Effects 
As the previous section indicates, there is inevitably a large amount of variability 
attributed to patients. Certainly, the input is much more variable when compared to 
typical manufacturing processes. Take, for example, a company that manufactures small 
precision cast iron parts. Every portion of the process is understood very well 
scientifically: the melting temperature of the iron, the strength of the mold cavity 
required, the hardening time, etc. Every piece is understood to a molecular level, and thus 
extremely high repeatability exists in the process and many high volume foundries report 
very low defect rates. To the contrary, IVF is a complex biological process with the 
outputs being live human beings. While vast knowledge is available in the biological and 
medical fields, it is well established that the human body is not understood as well as, 
say, molten metal. Even many parameters that are understood are impossible or at least 
very expensive and impractical to measure.  
Given that the inputs will not be able to be perfectly measured or controlled, it is 
important to take advantage of any information that is readily available in order to 
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understand the trends that exist. With this in mind, some patient factors have been found 
to be significant in predicting live birth rates in previous analyses such as age and 
maxFSH level (Ziebe et al., 2001; Frazier et al. 2004). Another study found the number 
of cryopreserved embryos to be significant, as this is an indication that the patient had a 
high number of viable embryos (Stern et al. 2009).  
Since we have demonstrated that Implantation rate correlates to live birth rate in 
the previous section, it will be appropriate to consider implantation rate as the output of 
interest for the remainder of this analysis. 
One of the first interesting things to look at in this exploratory study was the 
effects of the most obvious patient factor, age, and how prevalent it is in this dataset. 
Previous studies have overwhelmingly pointed to a decline in production of oocytes and 
high quality embryos the mid 30’s. In the SART data, these findings were echoed. 
 Figure 4 shows the trend of oocyte production by age from the women of various 
ages. The dataset contained patients from ages 19-52, however sample sizes were small 
(<25) outside of the 24-48 age range. An unexplained spike downward occurred for the 
group of 169 23-year-old patients. Overall, the trend was clearly downward. 
 
Figure 4: Average Oocytes Retrieved by Age 
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To measure the embryo quality from each age group, implantation rate was used. 
The average PEIR by age is shown here: 
   
Figure 5: Average PEIR by Age 
Initial exploration of the data reveals that the dataset is consistent with the 
findings of previous studies on effects of patient age. PEIR drops considerably as patients 
age. The average implantation rate can be modeled very accurately by the 4
th
 degree 
polynomial shown in Figure 5. 
Additionally, patient Body Mass Index (BMI) and smoker (Y/N) can be derived 
from the dataset. Each was considered and for significance independently. BMI is 
calculated from the given patient heights and weights. Patients are grouped by 
underweight, normal, overweight and obese. The mean PEIR is shown for each group in 
Figure 6. 
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Figure 6: PEIR by Patient BMI 
The comparison of PEIR by smoking status is shown in Figure 7. There is no 
practical difference between the groups, with smokers showing marginally higher PEIR 
on average.  
 
Figure 7: PEIR by Smoking Status 
3.2 Development of Tools 
One major goal of this paper is to propose a method for scoring day 3 and day 5 
embryos derived directly from actual results. Developing this measurement of embryo 
quality is an essential prerequisite for making comparisons between clinics. Additionally, 
scoring embryos will enable practitioners to better assess their risk of twinning or HOM 
pregnancies given the number of embryos transferred. 
The need to have a universal and reliable method of scoring embryos has been 
well established, and several attempts have been made in developing scoring systems 
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(Ziebe et al. 1997; Desai et al., 200) since Cummins’ initial attempt in the 80s. The 
problem is that none of these systems are empirically derived from large datasets. In 
Cummins’ case, and all other attempts up until Racowsky et al. (2013), it seems that the 
researchers followed a similar process: they examined the information that was available 
to them and found which factors were significant. Then, they converted values in each of 
these categories to a scoring system via a weighting. There are two main problems with 
this: 
1. The relative weighting of factor effects is not effectively balanced.  
2. It ignores potential interactions between variables (e.g. fragmentation and 
symmetry in day 3 embryos may have an interaction at various levels of each) 
To avoid these problems, this analysis opts to omit the intermediate translational steps 
and instead derives the one-dimensional score directly from real results. As the previous 
section explains, the best measure of embryo performance is Per Embryo Implantation 
Rate (PEIR). This directly measures an embryo’s capability to result in a pregnancy. 
The descriptors reported in the SART dataset are different depending on the 
Embryo’s Stage as detailed in       .  
 Table 8: Embryo Descriptors in SART dataset 
Stage Reported Descriptors 
Day 3 Number of Cells (1-8, >8), Symmetry (Perfect, Mod. Asymmetry, Severe 
Asymmetry), and Fragmentation (0, 1-10%, 11-25%, >25%) 
Morula Compaction (Complete, Incomplete), Fragmentation (0, 1-10%, 11-25%, 
>25%) 
Blastocyst Stage (Early, Expanded, Hatching),  Inner-cell mass (Good, Fair, Poor), 
Trophoblast (Good, Fair, Poor) 
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Together these descriptors make up a morphology combination for each embryo. 
We generated a score for each particular morphology combination based on the average 
PEIR rate of that embryo type. For example, if 100 embryos are transferred on day 3 that 
are 8-cell embryo with moderate asymmetry and no fragmentation, and 26 implantations 
are resultant, this morphology combination would be assigned a score of 0.26.  
A few obstacles exist in deriving this value from the dataset, so a several steps are 
required in making these calculations. The arranging and tallying of the data was 
performed in Microsoft Excel 2010.  In the data provided by SART, each cycle represents 
a row, and up to 5 embryo’s morphological characteristics are tracked. For each cycle, 
the number of embryos transferred is tracked and the number of implantations is 
calculated as described in the previous section.  
The target is to draw conclusions about the performance of individual embryos, so 
the rows of data must be converted to embryos instead of cycle. Of the 36836 cycles 
contained in the dataset, the distribution of embryos transferred is shown in Table 9. 
Table 9: Quantity of Embryos Transferred 
 
 
Thus, there exists morphological data for 74657 total embryos. From here a few 
reductions need to be made to reflect actual entries. First, there are 6685 cases where 
―NULL‖ values exist because this patient only had cryopreserved embryos and no fresh 
embryos were transferred. The next challenge that arises is that it is impossible to know 
which embryo successfully implanted in the case when multiple embryos were 
Embryos Transferred Number of Cycles
1 12212
2 15565
3 5926
4 2128
5+ 1005
41 
 
transferred. As previous researchers encountering this dilemma have done (Racowsky et 
al., 2003), the results will be derived from all cases when it can be known for sure the 
morphology of the embryos that implanted. These include the following situations:  
1. No embryos implanted (e.g. 3 embryos are transferred and 0 implant)  
2. All transferred embryos implant (e.g. 2 embryos are transferred and both implant)  
3. All of the embryos transferred are morphologically identical (e.g. 2 Early Stage  
blastocysts are transferred with good inner cell mass and good trophoblast) 
Although these seem like fairly specific cases, they actually span a good portion of 
the data available and fortunately maintain the integrity and power of the large dataset. 
The first two groups account for 36,693 embryos. After including all morphologically 
identical cycles (case 3), 46,267 remain with known implantation result.  
The case of morphologically identical embryos is handled by giving each embryo 
―partial credit‖ equal to the portion of embryos that implant. In other words, if 4 identical 
embryos are transferred and 1 implants, each embryo is given credit for .25 
implantations. The total of these four rows would then be 1 implantation for 4 embryos 
transferred. 
From this very large sampling, the performance of a particular morphology 
combination can be shown. Developing a regression model was considered, however 
because many of the variables are categorical, the model would need nearly as many 
terms as there are groupings particularly if any interaction terms were included.  It was 
most logical to instead develop contingency tables that calculate the PEIR for each 
treatment based on an average performance of all embryos of that type. As demonstrated 
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in the earlier section, patient age has a very significant impact on implantation rate and 
separate  
The data is brought into relational database software, Microsoft Access 2010, 
where it is grouped by each descriptor. An example of the query used can be found in 
Appendix C.2. The result is an average implantation rate for each embryo type. 
Table 10 shows the average implantation rate of each embryo combination for Day 3 
Embryos in patients under 36. Table 11 and Table 12 show the other patient age groups. 
A confidence level is established for each group based on the sample size considered. 
The PEIR is a proportion therefore it follows the binomial distribution. The Standard 
Error can be estimated by the normal approximation as shown in Equation 2. 
                                     
                      
                             
                                     
 
   ̂             ̂      √
 ̂(   ̂)
 
                   Equation 1 
    
Because some groups have small sample sizes, the Agresti-Coull method is used for 
slightly better accuracy. For the sake of consistency, Agresti-Coull intervals are used in 
all cases. Equations 2 and 3 show the adjustment. 
 ̃   
   
   
      ̃                                                             Equation 2 
   ̃             ̃      √
 ̃(   ̃)
 ̃
                   Equation 3 
A +/- 1.96 SE range is shown in the tables indicative of a 95% confidence interval. 
Groups with np<5 were not scored as the normal approximation is inaccurate. As a 
result, no severely asymmetric embryos were scored. From the entire dataset, 668 
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severely asymmetric embryos were transferred, resulting in 21 successful implantations, 
an IR of 3.1%. Perhaps, future studies can increase significance in these more uncommon 
groupings.  
In the case of an IR of zero, the sample size is shown in parentheses in lieu of the 
confidence interval. See Appendix A for the sample size of embryos from all categories. 
Note that in some cases the Confidence bounds extend below 0. Implantation Rates are 
proportions and are of course bounded by 0 and 1.  
Table 10: Day 3 PEIR and Confidence Intervals for Patients Age <36 
 
 
Table 11: Day 3 PEIR and Confidence Intervals for Patients Age 36-39 
 
 
 
 
 
0 1-10% 11-25% 0 1-10% 11-25%
1 cell
2 cell
3 cell
4 cell 11.1%  +/- 5.7% 18.2%  +/- 8.1% 22.2%  +/- 13.6%
5 cell 24.2%  +/- 14.6% 13.3%  +/- 7.3% 14.1%  +/- 8.5%
6 cell 19.6%  +/- 7.5% 12.0%  +/- 5.7% 18.6%  +/- 9.9% 14.4%  +/- 5.1% 11.4%  +/- 5.6%
7 cell 34.1%  +/- 8.1% 29.6%  +/- 8.0% 28.2%  +/- 10.0% 22.9%  +/- 6.7% 16.0%  +/- 7.2%
8 cell 37.3%  +/- 2.7% 36.4%  +/- 3.4% 31.0%  +/- 10.8% 43.8%  +/- 6.0% 28.8%  +/- 4.1% 20.5%  +/- 6.6%
>8cell 26.8%  +/- 8.8% 20.2%  +/- 7.9% 22.9%  +/- 13.9% 18.5%  +/- 8.5% 24.1%  +/- 15.6%
Contingency Table: Day 3 Per Embryo Implantation Rates
Cell Count
Perfect Symmetry Moderate Asymmetry
Fragmentation Fragmentation
Age <36
0 1-10% 11-25% 0 1-10% 11-25%
1 cell
2 cell
3 cell
4 cell 8.2%  +/- 5.6%
5 cell
6 cell 13.1%  +/- 6.8% 11.0%  +/- 6.0% 4.9%  +/- 3.6%
7 cell 8.1%  +/- 5.5% 14.8%  +/- 6.4% 13.8%  +/- 9.1% 16.7%  +/- 6.6%
8 cell 26.0%  +/- 3.1% 20.7%  +/- 3.8% 12.1%  +/- 8.6% 26.1%  +/- 6.9% 21.5%  +/- 5.0% 10.9%  +/- 5.5%
>8cell 21.7%  +/- 10.6% 12.9%  +/- 8.0% 21.9%  +/- 14.6% 13.3%  +/- 8.8%
Contingency Table: Day 3 Per Embryo Implantation Rates
Age 36-39
Perfect Symmetry Moderate Asymmetry
Fragmentation Fragmentation
Cell Count
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Table 12: Day 3 PEIR and Confidence Intervals for Patients Age >39 
 
The tables are color coded to make the trends more visible, with green reflecting the 
highest implantation rate and red reflecting the lowest implantation rates.   Interestingly 
in patients under 35, the overall implantation rate is highest for moderately asymmetric 8-
cell unfragmented embryos (n=256) over those with perfect symmetry (n=1188).  
Day 5 embryos can come in two flavors: Morulas and Blastocysts. Each are scored using 
different criteria as described in Table 13 and Table 15 below detail the mean PEIRs and 
95% confidence intervals for Morulas, using the same calculation methodology as above. 
Table 13: Morula Contingency Table Age <36  
 
 
Table 14: Morula Contingency Table Age 36 – 39 
 
Table 15: Morula Contingency Table Age >39 
 
0 1-10% 11-25% 0 1-10% 11-25%
1 cell
2 cell
3 cell
4 cell
5 cell
6 cell 8.3%  +/- 6.0%
7 cell 8.5%  +/- 6.2%
8 cell 6.8%  +/- 1.9% 4.8%  +/- 1.9% 5.9%  +/- 2.8% 5.1%  +/- 3.7%
>8cell
Contingency Table: Day 3 Per Embryo Implantation Rates
Cell Count
Age >39
Perfect Symmetry Moderate Asymmetry
Fragmentation Fragmentation
0 1-10% 11-25% 0 1-10% 11-25%
Morula 13.9%  +/- 2.8% 19.4%  +/- 4.0% 18.6%  +/- 5.0% 23.9%  +/- 5.1% 14.4%  +/- 5.3%
Age <36
Compaction Incomplete Compaction
Fragmentation Fragmentation
0 1-10% 11-25% 0 1-10% 11-25%
Morula 25.4%  +/- 4.6% 11.7%  +/- 4.1% 26.9%  +/- 8.7% 17.4%  +/- 5.8%
Compaction Incomplete Compaction
FragmentationFragmentationAge 36-39
0 1-10% 11-25% 0 1-10% 11-25%
Morula 17.6%  +/- 5.2%
Incomplete Compaction
Age >39
Compaction
Fragmentation Fragmentation
45 
 
The Morula tables were somewhat inconclusive due to low sample sizes. This is 
evident by the lack of clear trends and high standard deviations. Nonetheless, it is a start 
at representation of embryo performance. 
Blastocysts represent the most developed embryos that are transferred on day 5. 
On average, they are the most viable type of embryo transferred. The performance of 
each blastocyst morphology group is shown in the Table 16Table 18 below. 
Table 16: Blastocyst Contingency Table Age <36 
 
 
Table 17: Blastocyst Contingency Table Age 36-39 
 
 
Table 18: Blastocyst Contingency Table Age >39 
 
 
In contrast to the Morula tables, the blastocyst tables show very clear and 
predictable trends within each age grouping. Almost universally, the average 
performance increases toward the lower left corner of the chart indicating that more 
developed blastocysts with better inner cell mass and trophoblast are better performing.  
Good Fair Poor Good Fair Poor Good Fair Poor
Early Blast 45.1%  +/- 3.9% 53.3%  +/- 14.6% 51.4%  +/- 8.2% 36.8%  +/- 4.6% 45.5%  +/- 29.4% 41.7%  +/- 16.1% 30.0%  +/- 11.6%
Expanded Blast 61.6%  +/- 1.7% 63.1%  +/- 6.8% 56.4%  +/- 4.6% 53.2%  +/- 4.8% 41.7%  +/- 16.1% 31.3%  +/- 16.1% 40.0%  +/- 16.2% 40.7%  +/- 18.5%
Hatching Blast 63.8%  +/- 3.4% 62.3%  +/- 13.1% 56.6%  +/- 9.8% 50.7%  +/- 11.3% 62.5%  +/- 33.5% 50.0%  +/- 28.3%
Contingency Table: Blastocyst Implantation Rates
Good Trophoblast Fair Trophoblast Poor Trophoblast
Inner Cell Mass Inner Cell Mass Inner Cell Mass
Stage
Good Fair Poor Good Fair Poor Good Fair Poor
Early Blast 27.5%  +/- 6.1% 33.3%  +/- 20.2% 28.6%  +/- 11.2% 29.9%  +/- 6.3% 25.0%  +/- 17.3% 13.9%  +/- 11.3%
Expanded Blast 50.3%  +/- 3.2% 48.8%  +/- 11.0% 44.0%  +/- 6.9% 37.6%  +/- 7.4% 23.1%  +/- 16.2%
Hatching Blast 53.9%  +/- 6.4% 50.0%  +/- 24.5% 39.0%  +/- 14.9% 39.6%  +/- 13.8%
Contingency Table: Blastocyst Implantation Rates
Good Trophoblast Fair Trophoblast Poor Trophoblast
Inner Cell Mass Inner Cell Mass Inner Cell Mass
Stage
Good Fair Poor Good Fair Poor Good Fair Poor
Early Blast 16.2%  +/- 6.3% 20.0%  +/- 15.7% 13.8%  +/- 7.0%
Expanded Blast 28.6%  +/- 5.3% 20.0%  +/- 14.3% 11.1%  +/- 7.8% 14.0%  +/- 6.8%
Hatching Blast 34.7%  +/- 11.0% 38.5%  +/- 26.4% 34.5%  +/- 17.3% 22.2%  +/- 15.7%
Stage
Contingency Table: Blastocyst Implantation Rates
Good Trophoblast Fair Trophoblast Poor Trophoblast
Inner Cell Mass Inner Cell Mass Inner Cell Mass
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These contingency tables show with indicated confidence the performance that 
can be expected from each embryo morphology combination. This is a one-dimensional 
metric of quality.  
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CHAPTER 4: ANALYSIS AND RESULTS 
Now that an empirically derived and accurate embryo scoring methodology has 
been developed, it can be used for a variety of applications. One such application is 
making comparisons in the ability of clinics to grow viable embryos. Growing 
morphologically superior embryos will ultimately result in better live birth rates and 
reduce the number of embryos needed to be transferred per patient. Morphologically 
superior embryos are defined as those that are historically more viable as illustrated by 
the contingency tables. Naturally, these are goals that all clinics strive for. 
From the contingency tables, embryos are assigned a one dimensional score based 
on mean performance. For example, 6-cell, perfectly symmetric, nonfragmented embryos 
transferred on day 3 have resulted in 19 implantations over 103 transfers, so the score for 
that embryo in patients under 36 is: 0.184. An embryo’s viability can be effectively 
measured by this empirically derived score. 
The confidence in each score is based on the number of embryos of that particular 
morphology considered in the dataset. Figure 8 provides a visual representation of the 
contingency table. A 95% confidence interval is shown for each group’s average PEIR. 
The remaining patient age groups and the charts for blastocysts can be found in Appendix 
D. 
In the context of comparing clinics, it is important to note that the ―same embryo‖ 
e.g. Perfect, 8-cell, nonfragmented, Day 3 transfer from a 40 year old patient is not as 
viable as an embryo from a 30 year old with the same descriptive values. Accordingly, 
age is also factored into the groupings in the contingency tables.  
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Figure 8: PEIR Confidence Intervals for Day 3 Emrbyos, Patient Age < 36 
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Once the scores have been established for each grouping, the first logical 
comparison of clinics is: how viable are the embryos that they are producing? The SART 
data collected from 40 clinics over 3 years was used to develop the contingency tables 
which assign scores to all embryos with sufficient sample size to be confident in the 
value. Starting with the 46,266 embryos transferred, each is matched with their embryo 
grouping, be it a Day 3 cleavage stage embryo, Morula, or Blastocyst. A good portion of 
these embryos did not contain complete information in the form of having ―Unknown‖ or 
―Not entered‖ values in some columns. Also, those that were aligned with combinations 
that did not have sufficient sample size to produce a standard deviation of less than 10% 
were not included.  23,676 embryos remained for clinic comparisons.  
The mean embryo score for each clinic decile is shown in Figure 9: 
 
Figure 9: Mean Implantation Rate by Clinic Decile 
An ANOVA was performed in JMP 11.0 and a highly significant difference was 
found between the clinic mean embryo scores (p<.001). Table 19 shows the ANOVA 
table. 
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Table 19: ANOVA of Mean Embryo Score by Clinic 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Percentile Group 9 65.3200 7.25778 162.2853 <.0001* 
Error 23666 1058.3995 0.04472   
C. Total 23675 1123.7195    
 
Statistically significant differences exist between the groups not sharing the same 
letter in the Tukey-Kramer HSD comparison in  Figure 10 below.  
Level         Mean 
90 A       0.40788018 
80 A       0.39189709 
50   B     0.33670273 
40   B     0.32724649 
60   B     0.31793142 
70     C   0.28368505 
1       D 0.25545085 
20       D 0.25408793 
10       D 0.25263409 
30       D 0.23837105 
 Figure 10:  Connecting Letters Report 
The top two deciles show significantly higher embryo scores than the rest of the 
group. The 70
th 
percentile group appears to be the only group that doesn’t logically 
parallel the trend of live birth rate. This is because the 70
th
 percentile group has the 
largest portion of patients over age 35. Overall though, the upward trend is clear.  
It is evident that the better performing clinics (80
th
 and 90
th
 percentile) produce 
more viable embryos on average when compared to the lower performing clinics deciles. 
One potential cause for this difference in score is that Day 5 transfers have over 
2.5x the average performance compared to Day 3 transfers. The mean embryo score for 
Day 3 transfers is 16.4% compared to 43.6% for Day 5 transfers. The higher performing 
clinics make a larger portion of their transfers on Day 5 (Figure 11). 
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Figure 11: Day of Transfer by Clinic 
Surely, a good portion of the difference is coming from the higher ratio of Day 5 
to Day 3 transfers. An initial reaction to this might be to ask, why not simply transfer 
more embryos on day 5? One thing to keep in mind is that the reason why clinics transfer 
on Day 5 instead of Day 3. If the doctor plans to transfer two embryos in this patient and 
only two live embryos are remaining on Day 3, they will transfer those two embryos at 
that time. In another case, the conditions may be more favorable and there could be 5 
good quality embryos available on day 3. In the latter case it makes sense to wait until 
day 5 and see which embryos develop the best, and at which point transfer the best 
embryos. Waiting until day 5 gives the doctor more information about how normally an 
embryo will develop. So, making a higher portion of transfers on day 5 is less of a 
decision and more of an indication of the clinic’s ability to grow multiple good embryos. 
Nonetheless, it is interesting to consider individually whether the better clinics are 
producing morphologically superior embryos within a day of transfer. Looking at Day 3 
embryos only, the mean embryo scores by clinic are shown below (Figure 12). There 
does not appear to be any significant trend in the data.  
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Figure 12: Day 3 Mean Embryo Score by Clinic Decile 
The analysis is repeated for Day 5 (Figure 13). 
 
Figure 13: Day 5 Mean Embryo Score by Clinic Decile 
While the difference is not extremely pronounced, a Tukey-Kramer comparison 
reveals that a significant difference exists between the lower 4 and the top 6 deciles with 
the exception of the 70
th
 and 20
th
 percentile groups showing no significant difference. 
The JMP output can be found in Appendix B. This indicates that the better performing 
clinics produce significantly more viable Day 5 embryos on average when compared to 
the lower performing clinics. 
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The high performing clinics are producing morphologically superior embryos on 
average. The next question that arises is: do morphologically equivalent embryos result in 
higher implantation rates at the best clinics? There are several ways to approach this; one 
would be to look within individual groups. The largest groups from each day of transfer 
are described in Table 20 below. 
Table 20: Most Plentiful Embryo Combinations 
 
 In each case, the performance of this particular embryo type is compared among 
the clinics. Results are as follows: 
 
Figure 14: Performance of 8-cell, Symmetric, Nonfragmented Embryos by Clinic Decile 
With the exception of the 30
th
 decile, there is a very strong upward trend in the 
performance of the optimal Day 3 transferred embryos. The mean implantation rate of 
these embryos that have the exact same values based on SART’s scoring categories is 
.455 in the top decile compared to .214 in the lowest, over a 2 fold increase. This has 
some very important implications when using the contingency tables for predictive value 
which are discussed in detail in the conclusion section.  
Age Morphology Embryo Score Quantity
<36 Expanded Blast, Good, Good 0.616 3273
<36 8 cell , 0 Frag. ,Perfect Sym. 0.373 1188
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Now, consider the embryo that is most abundant (n=3273): Blastocysts from 
young patients (<36) with good inner cell mass and trophoblastic scores transferred on 
Day 5. These show an overall average IR of 61.6%. 
 
Figure 15: Performance of Good Expanded Blastocysts by Clinic Decile 
Again, as shown in Figure 15, a strong upward trend is present, with a notable 
separation between the top 4 deciles and the remaining groups. 
So, it is clear that a difference in performance exists independently in these 
groups. How can this be compared in the overall dataset, though? Taking a more holistic 
approach, consider the performance of each embryo relative to what it’s score predicts in 
each case. This can be done by looking at the relative performance of each entry as: 
                        (             )    (            ) 
       In the example of the expanded blastocysts above, this value would be derived by the 
(bar height) – line. Essentially, this takes an overall weighted average of the analysis 
above being performed for each embryo grouping.  Another way of thinking about this is: 
the performance of an embryo relative to what it’s score would predict. Figure 16 shows 
the mean expected performance, measured by average embryo score at each clinic decile. 
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Actual performance in the chart is derived from the total implantations divided by total 
number of embryos transferred in that decile. 
 
Figure 16: Implantation Rate by Clinic 
Taking the difference between the two lines, mean relative performance is calculated for 
each decile: 
 
Figure 17: Mean Relative Value by Clinic 
This graph is very interesting as it affirms the conclusions made within the most 
common embryo morphologies span the entire dataset. The spike in the 30
th
 percentile 
clinics is also intriguing.  Recall  Figure 10 and notice that the 30
th
 percentile clinics had 
the lowest overall embryo score. These clinics had particularly bad embryos 
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morphologically and produced better than expected results with them. One possible 
explanation is stricter grading of embryos relative to the other practitioners. 
Also, an ANOVA reveals that there is a significant difference in relative 
performance among the clinics (p<.001). The ANOVA results are in Table 21.  
Table 21: ANOVA of Relative Performance by Clinic 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
PercentileGroup 9 49.3869 5.48744 43.1734 <.0001* 
Error 23639 3004.5705 0.12710   
C. Total 23648 3053.9574    
 
The connecting report can be found in Appendix B.  Morphologically equivalent 
embryos have significantly higher implantation rates at the best performing clinics. 
This conclusion is not confounded by age or day of transfer and proposes 
opposing evidence to the argument typically made by the lower performing clinics that 
their lower success rates are due to patients. Granted, other factors could still be in play. 
Further research will be needed to examine the role of patient diagnosis. 
The purpose of the clinic comparisons were to dive deeply into the differences 
and try to better understand why such a large disparity exists in live birth rates among 
clinics. The clinics included in this study are sprinkled across the rankings of live birth 
rate, so obviously there is a difference in live birth rates. The interesting part is breaking 
down the process and understanding which portions are the source of difference. It was 
shown that there is not a significant difference in oocyte production among clinics. Also, 
the translation between IR and live births per embryo transferred seemed to be relatively 
constant with the exception of the poorest two clinic groupings. The cause of these lowest 
two groupings lagging behind is unknown, although it certainly provides an opportunity 
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for a future studies to be performed exploring causes for differences in live births per 
implantation.  
Given the relative equality of the beginning and end of the IVF process, what 
remains is the portion in which the clinic is most involved: the development from oocyte 
to transferable embryo. The majority of the variation in live birth rate is attributed to this 
stage. Clinic performance in this stage was assessed and compared in this thesis. 
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CHAPTER 5: CONCLUSIONS 
       This exploratory study aimed to do several things. The initial purpose was to 
develop a foundation for understanding of embryo performance by applying statistical 
analysis techniques to a large dataset of IVF cycles. The data was thoroughly examined 
to see what areas can be better understood. The main accomplishment of this thesis was 
to propose a new embryo scoring method and to use the scores to make comparisons 
between clinics.  
       The embryo scores generated in the contingency tables are uniquely valuable 
because they are the first of their kind: derived directly from the average performance of 
that particular embryo in terms of the most relevant metric, PEIR. Implantation rate 
measures an embryo’s ability to result in a pregnancy.  
Given that the contingency tables calculate the PEIR for each treatment based on 
average performance of all embryos of that type, clinics now have a baseline for the 
relative performance of embryos of given morphologies. By comparing their historic 
success to the mean of the contingency tables, 30% implantation rate, they can make 
adjustments to their practices accordingly. 
       A one-dimensional embryo scoring metric was essential to facilitate the 
comparison made in this paper, and ultimately several conclusions drawn. First, the better 
clinics produce morphologically superior embryos in terms of embryo score. 
Additionally, it was demonstrated that embryos of identical morphology perform better at 
the higher percentile clinics.   
Having a baseline for embryo performance allows clinics to better understand and 
control variation in the IVF process. Hopefully, this metric will be adopted by the 
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community. The great thing about this metric is that the more it is used, the more reliable 
the mean performance estimate for each morphology combination becomes. If further 
studies are performed using this metric, they can juxtapose their data on top of this data 
to increase significance.  
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CHAPTER 6: RECOMMENDATIONS FOR FUTURE STUDY 
The actual performance of clinics differs more than the disparity of embryo scores 
predict it would. This indicates that there is more to the embryo’s viability than is 
captured by the SART descriptors. Further and more detailed embryo assessment and 
tracking should be considered. Additionally, experiments should be performed to 
understand the effects of clinic based factors. A study within a particular clinic 
comparing performance of embryos before and after a change is made such as 
temperature, air quality, or procedural method, could produce interesting results. The 
contingency tables generated in this study offer a basis for performing such analyses.   
Also, other patient based factors could be in play. Future study exploring the 
exact effects on other measurable patient factors can further add to the predictability of 
treatment outcomes.  
Another area to build upon this study is analyzing the variability in embryo 
quality developed from one patient. In the context of IVF, it would be very challenging to 
develop a paired comparison between clinics, because it is unlikely a patient will be 
willing to sign up for multiple IVF procedures at different clinics. However, a unique 
opportunity exists to compare the variability in embryo quality while removing patient 
effect: compare the quality of embryos from a single patient. The limitation in the SART 
dataset is that it only tracks the embryos that are transferred, the cream of the crop from 
all of the oocytes ―cultivated‖. In order to properly perform this analysis, a morphological 
breakdown is necessary for all embryos grown by a clinic, not just those that are 
transferred.         
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APPENDICES 
Appendix A: Contingency Table Sample Sizes 
 
0 1-10% 11-25% 0 1-10% 11-25% 0 1-10% 11-25%
1 cell
2 cell
3 cell
4 cell 113 84 32 71 53
5 cell 37 43 29 79 60
6 cell 103 121 55 176 119
7 cell 128 121 74 149 96
8 cell 1188 755 67 256 468 142 12
>8cell 93 95 31 77 25
0 1-10% 11-25% 0 1-10% 11-25% 0 1-10% 11-25%
1 cell
2 cell
3 cell
4 cell 93 74 35 73 53
5 cell 37 46 38 95 78
6 cell 95 105 46 140 111
7 cell 95 118 27 54 122 65
8 cell 777 451 54 157 271 125
>8cell 56 66 28 56 30
0 1-10% 11-25% 0 1-10% 11-25% 0 1-10% 11-25%
1 cell
2 cell
3 cell
4 cell 154 98 36 131 76 15
5 cell 50 59 49 115 77
6 cell 126 122 29 80 162 132
7 cell 143 123 26 78 153 101
8 cell 686 512 49 143 269 134
>8cell 73 101 26 53 41
Age >39
Contingency Table: Day 3 Sample Sizes
Perfect Symmetry Moderate Asymmetry Severe Assymetry
Fragmentation Fragmentation Fragmentation
Cell Count
Age 36-39
Contingency Table: Day 3 Sample Sizes
Perfect Symmetry Moderate Asymmetry Severe Assymetry
Fragmentation Fragmentation Fragmentation
Cell Count
Age <36
Contingency Table: Day 3 Sample Sizes
Perfect Symmetry Moderate Asymmetry Severe Assymetry
Fragmentation Fragmentation Fragmentation
Cell Count
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0 1-10% 11-25% 0 1-10% 11-25%
Morula 145 94 20 56 65 40
0 1-10% 11-25% 0 1-10% 11-25%
Morula 86 56 22 39 33 32
0 1-10% 11-25% 0 1-10% 11-25%
Morula 50 37 10 25 38 32
Age >39
Compaction Incomplete Compaction
Fragmentation Fragmentation
Age 36-39
Compaction Incomplete Compaction
Fragmentation Fragmentation
Age <36
Compaction Incomplete Compaction
Fragmentation Fragmentation
Good Fair Poor Good Fair Poor Good Fair Poor
Early Blast 613 41 138 420 32 56
Expanded Blast 3273 191 448 415 32 28 31
Hatching Blast 776 49 95 71
Good Fair Poor Good Fair Poor Good Fair Poor
Early Blast 203 59 197 20 32
Expanded Blast 928 76 196 161 22 14
Hatching Blast 226 37 44
Good Fair Poor Good Fair Poor Good Fair Poor
Early Blast 126 21 90 18
Expanded Blast 272 26 59 96
Hatching Blast 68 25 23
Age >39
Contingency Table: Blastocyst Sample Size
Good Trophoblast Fair Trophoblast Poor Trophoblast
Inner Cell Mass Inner Cell Mass Inner Cell Mass
Stage
Age 36-39
Contingency Table: Blastocyst Sample Size
Good Trophoblast Fair Trophoblast Poor Trophoblast
Inner Cell Mass Inner Cell Mass Inner Cell Mass
Stage
Age <36
Contingency Table: Blastocyst Sample Size
Good Trophoblast Fair Trophoblast Poor Trophoblast
Inner Cell Mass Inner Cell Mass Inner Cell Mass
Stage
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Appendix B: JMP Outputs 
B.1 Comparison of Day 5 scores by clinic 
 
Connecting Letters Report 
 
Level             Mean 
90 A           0.51803801 
40 A B         0.50224059 
50 A B         0.50210710 
80 A B         0.49916117 
60   B C       0.48506333 
70     C D     0.46930236 
20       D E   0.45253568 
1       D E F 0.44165333 
10         E F 0.43135228 
30           F 0.41796677 
 
Levels not connected by same letter are significantly different. 
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B.2 Relative Value 
Connecting Letters Report 
 
Level             Mean 
60 A        0.0535446 
90 A        0.0447630 
80 A        0.0317730 
70 A        0.0294183 
30 A        0.0279788 
40   B       -0.0360669 
50   B       -0.0372175 
10   B       -0.0485057 
20   B       -0.0580537 
1     C     -0.1208109 
 
Levels not connected by same letter are significantly different. 
 
Appendix C: Formulas and Queries  
C.1 Implantations Calculation 
 
C.2 Contingency Generation Query 
 
Appendix D: Contingency Table Confidence Ranges  
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